Predictive Biosciences snaps up OncoDiagnostic Laboratory
This article was originally published in The Gray Sheet
Acquisition of privately held, CLIA-certified anatomic pathology and molecular diagnostics lab OncoDiagnostic Laboratory for undisclosed terms on Jan. 7 by cancer test maker Predictive Biosciences will facilitate commercialization in 2010 of the latter firm's non-invasive molecular cancer diagnostic assays. The first assay will be a urine biomarker test for bladder cancer, Predictive Biosciences says. Cleveland-based OncoDiagnostic's "subspecialty expertise and national access to hundreds of urology practices [will] favorably position" Lexington, Mass.-based Predictive for launching its bladder cancer test "as well as future diagnostic products," including prostate and breast cancer assays, Predictive Biosciences explains
You may also be interested in...
Following hot on the heels of its Rapidly Manufactured Ventilator Specification document, the UK’s regulator has issued another speedy regulatory permit for fast production of respiratory assist devices.
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.
China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.